Literature DB >> 15687351

Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis.

Guoqian Chen1, Jianhua Li, Xiaoling Qiang, Christopher J Czura, Mahendar Ochani, Kanta Ochani, Luis Ulloa, Huan Yang, Kevin J Tracey, Ping Wang, Andrew E Sama, Haichao Wang.   

Abstract

Stearoyl lysophosphatidylcholine (LPC) has recently been proven protective against lethal sepsis by stimulating neutrophils to eliminate invading pathogens through an H2O2-dependent mechanism. Here, we demonstrate that stearoyl LPC, but not caproyl LPC, significantly attenuates circulating high-mobility group box 1 (HMGB1) levels in endotoxemia and sepsis by suppressing endotoxin-induced HMGB1 release from macrophages/monocytes. Neutralizing antibodies against G2A, a potential cell surface receptor for LPC, partially abrogated stearoyl LPC-mediated suppression of HMGB1 release. Thus, stearoyl LPC confers protection against lethal experimental sepsis partly by facilitating the elimination of the invading pathogens and partly by inhibiting endotoxin-induced release of a late proinflammatory cytokine, HMGB1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15687351     DOI: 10.1194/jlr.C400018-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  59 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock.

Authors:  Oliver Murch; Marika Collin; Bruno Sepodes; Simon J Foster; Helder Mota-Filipe; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens.

Authors:  Esther M Sternberg
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

4.  Neuropeptide modulators of high mobility group box 1 secretion as potential therapeutic agents for severe sepsis.

Authors:  Mitchell P Fink
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

5.  G2A Protects Mice against Sepsis by Modulating Kupffer Cell Activation: Cooperativity with Adenosine Receptor 2b.

Authors:  Hong-Mei Li; Ji Hye Jang; Jun-Sub Jung; Jiseon Shin; Chul O Park; Yeon-Ja Kim; Won-Gyun Ahn; Ju-Suk Nam; Chang-Won Hong; Jongho Lee; Yu-Jin Jung; Jiang-Fan Chen; Katya Ravid; H Thomas Lee; Won-Ki Huh; Janusz H Kabarowski; Dong-Keun Song
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

Review 6.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1.

Authors:  Shu Zhu; Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-20

Review 8.  High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.

Authors:  Shu Zhu; Wei Li; Mary F Ward; Andrew E Sama; Haichao Wang
Journal:  Inflamm Allergy Drug Targets       Date:  2010-03

Review 9.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

Review 10.  G2A and LPC: regulatory functions in immunity.

Authors:  Janusz H Kabarowski
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-19       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.